A triazolyl thienyl-cyclohexane II A was discovered as a tractable starting point for a lead optimization effort in a cdk5 kinase inhibition program. SAR studies aided by the identification of selective inhibition of cdk5/p25 versus cdk2/cyclin E. The compounds V A, V B showed moderate where as compounds X A, X B showed significant inhibition of cdk5/p25 and thus have potential for treatment of Alzheimer's disease.
Loading....